Luke Miels Sells 4,549 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Luke Miels sold 4,549 shares of GSK stock in a transaction on Monday, February 9th. The shares were sold at an average price of GBX 2,211, for a total value of £100,578.39.

GSK Price Performance

Shares of GSK stock opened at GBX 2,141 on Friday. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. GSK plc has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 2,219. The company has a market cap of £86.38 billion, a P/E ratio of 16.10, a P/E/G ratio of 1.24 and a beta of 0.31. The business has a fifty day simple moving average of GBX 1,873.72 and a 200 day simple moving average of GBX 1,688.49.

GSK (LON:GSK) last released its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, sell-side analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on GSK. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Citigroup increased their price target on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research note on Monday. UBS Group restated a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Shore Capital Group reaffirmed a “buy” rating and issued a GBX 2,300 target price on shares of GSK in a report on Wednesday, February 4th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.